Octreotide scanning for carcinoid tumours
Open Access
- 1 July 1997
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 73 (861) , 399-402
- https://doi.org/10.1136/pgmj.73.861.399
Abstract
Summary: The somatostatin analogue octreotide may be used in the diagnosis of carcinoid and other neuroendocrine tumours. Radionuclide scanning following intravenous injection of 111Indium-labelled octreotide (111In-DTPA-pentetreotide) provides a sensitive, non-invasive method of localising somatostatin-positive tumours. The technique may also be used to identify patients who may respond to ‘cold’ octreotide therapy and to monitor therapeutic efficacy.Keywords
This publication has 12 references indexed in Scilit:
- Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.1995
- Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detectionBritish Journal of Surgery, 1994
- Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- A ticket to ride: peptide radiopharmaceuticals.1993
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Somatostatin analogue scintigraphy in carcinoid tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Radionuclide therapy revisitedEuropean Journal of Nuclear Medicine and Molecular Imaging, 1991
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989